Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY), the Indian drugmaker, on Wednesday reported a modest rise in third-quarter revenue but a notable decline in net profit as pressure from pricing and product-specific challenges weighed on earnings for the quarter ended Dec. 31, 2025. Revenue Growth Moderates; Profit Falls Consolidated revenue increased 4.4% year-on-year to ₹8,726.8 crore […]
Dr. Reddy’s Laboratories’ latest earnings show a modest rise in profit, but the real story extends far beyond the headline numbers. So, what’s driving this pharmaceutical powerhouse forward? Our latest video analysis breaks down the Q2 FY26 results, uncovering the company’s focus on global generics expansion, cost optimization, and steady progress in biosimilars and specialty segments. […]
Company Overview: Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr. Reddy’s Laboratories reported Total revenue for Q4FY25 of ₹ 9,050 Crore up from ₹7,311 Crore in Q4FY24, a […]
Dr Reddy’s Laboratories Ltd., an integrated global pharmaceutical company, in its Q3 earnings call discussed a 16% growth in India despite weakness in cardiac and GI segments, while its European business grew 22%. The company discussed its biosimilar strategy, including Rituximab, denosumab, and abatacept, targeting December 2025 filing. A major focus was the company’s Semaglutide […]
Dr. Reddy’s Laboratories ( NSE : DRREDDY) Q2 FY24 Earnings Concall dated Oct. 27, 2023 Corporate Participants: Richa Periwal — Head Of Investor Relations Parag Agarwal — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Mikaela Franceschina — Barclays — Analyst Kunal Dhamesha — Macquarie — Analyst Neha Manpuria — Bank of America […]
Dr. Reddy’s Laboratories (NSE:DRREDDY) Q4 FY23 Earnings Concall dated May. 10, 2023. Corporate Participants: Richa Periwal — Investor Relations G V Prasad — Co-Chairman and Managing Director Parag Agarwal — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Mikhaila — Barclays — Analyst Surya Patra — PhillipCapital — Analyst Damayanti Kerai — HSBC — Analyst Neha Manpuria — Bank of America — Analyst Ankush Mahajan — Axis Securities — Analyst Kunal […]
Key highlights from Dr. Reddy’s Laboratories (DRREDDY) Q4 FY23 Earnings Concall Q&A Highlights: [00:21:55] Mikhaila at Barclays asked more details about the deal with Junshi, including the responsibilities of both parties and what convinced DRREDDY about their asset and its potential. Erez Israeli CEO said the company seeks unmet needs in India and collaborates with […]
“We are progressing well on our pipeline products. The number of filings in several of our key markets have been improving. The ANDA and DMF filings are expected to significantly improve during Q4. We are evaluating several inorganic opportunities across businesses in line with our strategy. We believe, all of these will lead to several […]
Dr. Reddy’s Laboratories Ltd. (NSE:DRREDDY) is a multinational pharmaceutical company based in Hyderabad, India. The company was founded in 1984 and has since grown to become a leading player in the global pharmaceutical industry. Dr. Reddy’s Laboratories specializes in the development, manufacturing, and marketing of generic drugs, active pharmaceutical ingredients (APIs), and proprietary products. The […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) is an Indian multinational pharmaceutical company. Founded in 1984, the company primarily develops and sells a wide range of generic and over-the-counter drugs, as well as active pharmaceutical ingredients, and biopharmaceuticals. The company has operations in over 100 countries, with a focus on the developing world. It is known for […]